Thyroid nodules are very common in the general adult
|
|
- Mervin Hill
- 6 years ago
- Views:
Transcription
1 Next-Generation Sequencing Identifies Gene Mutations That Are Predictive of Malignancy in Residual Needle Rinses Collected From Fine-Needle Aspirations of Thyroid Nodules Maren Y. Fuller, MD; Dina Mody, MD; April Hull, CT(ASCP); Kristi Pepper, MT(ASCP); Heather Hendrickson, MT(ASCP); Randall Olsen, MD, PhD Context. Thyroid nodules have a prevalence of approximately 70% in adults. Fine-needle aspiration (FNA) is a minimally invasive, cost-effective, standard method to collect tissue from thyroid nodules for cytologic examination. However, approximately 15% of thyroid FNA specimens cannot be unambiguously diagnosed as benign or malignant. Objective. To investigate whether clinically actionable data can be obtained using next-generation sequencing of residual needle rinse material. Design. A total of 24 residual needle rinse specimens with malignant (n ¼ 6), indeterminate (n ¼ 9), or benign (n ¼ 9) thyroid FNA diagnoses were analyzed in our clinical molecular diagnostics laboratory using next-generation sequencing assays designed to detect gene mutations and translocations that commonly occur in thyroid cancer. Results were correlated with surgical diagnoses and clinical outcomes. Results. Interpretable data were generated from 23 of 24 residual needle rinse specimens. Consistent with its wellknown role in thyroid malignancy, BRAF V600E mutations were detected in 4 malignant cases. An NRAS mutation was detected in 1 benign case. No mutations were detected from specimens with indeterminate diagnoses. Conclusions. Our data demonstrate that residual thyroid FNA needle rinses are an adequate source of material for molecular diagnostic testing. Importantly, detection of a mutation implicated in thyroid malignancy was predictive of the final surgical diagnosis and clinical outcome. Our strategy to triage thyroid nodules with indeterminate cytology with molecular testing eliminates the need to perform additional FNA passes into dedicated media or to schedule additional invasive procedures. Further investigation with a larger sample size to confirm the clinical utility of our proposed strategy is underway. (Arch Pathol Lab Med. 2018;142: ; doi: / arpa oa) Thyroid nodules are very common in the general adult population, with a prevalence of approximately 70% in adults. 1 Most thyroid nodules are benign, but because of their high prevalence, thyroid cancer is fairly common. Importantly, for reasons that remain uncertain, the number of new cases consistently increases annually. 2 Fine-needle aspiration (FNA) biopsy is the standard method for a pathologist to examine thyroid nodules. Accepted for publication April 6, Published as an Early Online Release May 24, From the Department of Pathology & Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Drs Fuller, Mody, and Olsen, and Mss Hull, Pepper, and Hendrickson); and the Department of Pathology, Weill Cornell Medical College, New York, New York (Drs Mody and Olsen). The authors have no relevant financial interest in the products or companies described in this article. A poster based on our preliminary data was presented at the United States & Canadian Academy of Pathology 2017 Annual Meeting; March 6, 2017; San Antonio, Texas. Reprints: Maren Y. Fuller, MD, Department of Pathology & Genomic Medicine, Houston Methodist Hospital, 6565 Fannin, M227, Houston, TX ( marenfullermd@gmail.com; However, approximately 10% to 15% of thyroid FNAs cannot unequivocally be diagnosed as benign or malignant, and receive an indeterminate diagnosis. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was published in This internationally recognized standard includes 6 diagnostic categories, ranging from nondiagnostic/unsatisfactory to malignant. Most categories include an estimated risk of malignancy that guides further clinical management. Using TBSRTC, nearly 80% of thyroid FNAs can be categorized as either benign or malignant. The indeterminate categories include atypia of undetermined significance or follicular lesion of undetermined significance, and follicular neoplasm or suspicious for follicular neoplasm. The risk of malignancy in these categories is institution dependent, ranging from 5% to 15% for atypia of undetermined significance/follicular lesion of undetermined significance to 15% to 30% for follicular neoplasm/ suspicious for follicular neoplasm. The diagnostic challenge posed by indeterminate thyroid FNAs results in clinical uncertainty. Management of an indeterminate FNA may include clinical observation, repeat FNA, or surgical lobectomy. Important to patient safety, scheduling additional procedures may delay the diagnosis in cases that are malignant, and surgical lobectomy may risk 178 Arch Pathol Lab Med Vol 142, February 2018 Molecular Testing on Residual Thyroid FNAs Fuller et al
2 Cytology Diagnosis Cytology, Molecular, and Follow-up Results Gene Mutation(s) Detected a Follow-up Follow-up Gene Mutation(s) Detected a Benign NRAS Clinically no issues Benign None detected Clinically no issues Benign None detected Not available Benign None detected Not available Benign (Hashimoto) None detected Resection: benign (Hashimoto thyroiditis) Benign (Hashimoto) None detected Resection: benign (Hashimoto thyroiditis) Benign (Hashimoto) None detected Clinically no issues Benign (Hashimoto) None detected Clinically no issues Benign (Hashimoto) None detected Not available Atypical Insufficient for testing Resection: PTC BRAF V600E AUS None detected b Repeat FNA: AUS AUS None detected Not available AUS None detected Not available AUS None detected Not available AUS None detected Unrelated lung carcinoma; clinically no thyroid nodule issues Cyst (previous AUS) None detected c Clinically no issues Suspicious for follicular neoplasm None detected Resection: PTC, follicular variant None detected Suspicious for Hürthle cell neoplasm None detected Resection: Hurthle cell adenoma None detected Positive for malignancy (PTC) BRAF V600E Resection: PTC BRAF V600E Positive for malignancy (PTC) BRAF V600E Resection: PTC Not available Positive for malignancy (PTC) BRAF V600E Resection: PTC Not available Positive for malignancy (PTC) BRAF V600E Resection: PTC Not available Positive for malignancy (PTC) None detected Resection: PTC Not available Positive for malignancy (PTC) None detected Resection: follicular neoplasm with neuroendocrine features PTEN N323fs*21 Abbreviations: AUS, atypia of undetermined significance; FNA, fine-needle aspiration; PTC, papillary thyroid carcinoma. a Analysis was limited to mutations implicated in sporadic thyroid cancer. b KRAS G60R mutation was identified as an incidental finding. c KDR K286N and APC I1557Y were identified as incidental findings. overtreatment of benign nodules. An alternative strategy is to triage indeterminate thyroid FNAs for rapid molecular diagnostic testing. In support, the 2015 American Thyroid Association guidelines for thyroid nodules include recommendations for molecular testing. 4 Currently there are 3 major commercially available molecular tests for indeterminate thyroid FNAs. 5 They include the Afirma Gene Expression Classifier (Veracyte Inc, South San Francisco, California), ThyGenX/ThyraMIR (Interpace Diagnostics, PDI Inc, Parsippany, New Jersey), and ThyroSeq v2 (University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania). Of note, each of these tests requires dedicated thyroid FNA material into special collection media. This collection is done at the time of the FNA procedure, before the cytology diagnosis is rendered. In order to use these available tests, the patient must return for a second FNA. Alternatively, an extra FNA pass could be performed at the time of the first procedure for every patient, even though it will not be needed for the 80% of cases that will have a definitive cytology diagnosis rendered. Newer on the market is a molecular microrna-based assay, RosettaGX Reveal (Rosetta Genomics Inc, Philadelphia, Pennsylvania), which can be used on routinely prepared FNA slides. 6 Although many commercially available molecular tests require specimen collection in proprietary media, liquidbased cytology has been shown to be an adequate source for DNA and RNA for molecular testing A previous pilot study showed that FNA needle rinses in ThinPrep CytoLyt Solution (Hologic Inc, Marlborough, Massachusetts) are an acceptable specimen type for the ThyGenX molecular testing. 11 Our hypothesis is that clinically relevant molecular data can be obtained from the residual, routinely discarded needle rinse material from thyroid FNA specimens. MATERIALS AND METHODS Case Selection At the time of thyroid FNA, air-dried and alcohol-fixed smears are prepared from each pass, followed by the needle being rinsed in CytoLyt before being discarded. This needle rinse can be used to make an additional ThinPrep slide if the cellularity is low, or a cellblock if immunohistochemical stains are needed. In most cases, this residual needle rinse material is discarded. Residual thyroid FNA rinse material was collected from 24 specimens during a period of 5 months. The specimens were collected in ThinPrep CytoLyt solution (n ¼ 22) or in RPMI (n ¼ 2; Lonza Group AG, Basel, Switzerland). Thyroid FNA diagnoses were rendered by board-certified cytopathologists at Houston Methodist Hospital (Houston, Texas). Most cytology diagnoses followed TBSRTC. 3 Cases were selected for molecular testing based on cytology diagnosis, including 9 benign, 9 indeterminate, and 6 malignant nodules. Diagnoses that were considered indeterminate were atypia of undetermined significance/follicular lesion of undetermined significance, follicular neoplasm/suspicious for follicular neoplasm, and any non-tbsrtc diagnosis. Our study did not include any cases with the cytology diagnosis of suspicious for malignancy. One malignant case was a benchtop FNA of a surgical resection specimen with the diagnosis of papillary thyroid carcinoma that was used as a positive control. This study was approved by the Institutional Review Board at Houston Methodist Hospital. Arch Pathol Lab Med Vol 142, February 2018 Molecular Testing on Residual Thyroid FNAs Fuller et al 179
3 Figure 1. A and B, Thyroid fine-needle aspiration: atypical, insufficient for molecular testing. C and D, Resection: papillary thyroid carcinoma with BRAF V600E mutation (Diff-Quik stain, original magnification 3200 [A]; Papanicolaou stain, original magnification 3200 [B]; hematoxylin-eosin, original magnifications 3100 [C] and 3400 [D]). Specimen Storage Residual FNA needle rinse materials are routinely stored at 48C for 1 to 32 days (average, 14 days). Specimens selected for inclusion in this study were transferred to the molecular diagnostics laboratory and stored at 808C. Molecular Testing DNA/RNA extraction and molecular testing were performed in our clinical molecular diagnostics laboratory by a trained medical technologist blinded to the cytology diagnoses. DNA and RNA were isolated from the residual needle rinse specimens using an AllPrep DNA/RNA Mini preparation kit (Qiagen, Alameda, California) according to the manufacturer s protocol. Gene mutations were detected by next-generation sequencing performed on the extracted DNA. Ion PGM Template OT2 200 and Ion PGM Sequencing 200 kits (Life Technologies, San Francisco, California) were used according to the manufacturer s protocol. The assay detects mutations in approximately 200 targeted regions in 50 genes implicated in human malignancy. Tested genes include ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZF2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, and VHL. The limit of detection is 10% mutant allele burden at 1003 coverage. Gene translocations were detected by next-generation sequencing performed on the extracted RNA. The FusionPlex CTL Kit (ArcherDX, Boulder, Colorado) and a NextSeq Instrument (Illumina, San Diego, California) were used according to the manufacturers protocols. The assay detects gene rearrangements, splice site variants, and copy number variants in 195 targets in 40 genes implicated in thyroid and lung cancer. Tested genes include AKT1, ALK, AXL, BRAF, CALCA, CCND1, CTNNB1, DDR2, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, GNAS, HRAS, IDH1, IDH2, KRAS, KRT20, KRT7, MAP2K1, MET, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PIK3CA, PPARG, PTH, RAF1, RET, ROS1, SLC5A5, THADA, TTF1, CHMP2A, GPI, RAB7A, and VCP. Follow-up Surgical pathology follow-up was obtained from the laboratory information system. Clinical follow-up was obtained from the electronic medical record. RESULTS A total of 24 residual needle rinse specimens from thyroid FNAs from 22 patients were collected. All specimens would otherwise have been discarded. The cytology diagnoses 180 Arch Pathol Lab Med Vol 142, February 2018 Molecular Testing on Residual Thyroid FNAs Fuller et al
4 Figure 2. A and B, Thyroid fine-needle aspiration: suspicious for follicular neoplasm, no gene mutations detected. C and D, Resection: papillary thyroid carcinoma, follicular variant, no gene mutations detected (Diff-Quik stain, original magnification 3200 [A]; Papanicolaou stain, original magnification 3200 [B]; hematoxylin-eosin, original magnifications 3100 [C] and 3400 [D]). were benign (n ¼ 9), indeterminate (n ¼ 9), and malignant (n ¼ 6; Table). Adequate nucleic acid for gene mutation testing and gene translocation testing was isolated from 23 of 24 and 22 of 24 needle rinse specimens, respectively. One case with insufficient nucleic acid had very low cellularity, had a ThinPrep slide prepared to aid in the cytology diagnosis, and did not receive a diagnosis using the Bethesda System (Figure 1). Gene mutations were detected in 5 specimens, including 4 of 6 malignant (66.7%), 0 of 8 indeterminate, and 1 of 9 benign cases (Table). Consistent with its known role in thyroid tumors, a BRAF V600E mutation was detected in the 4 positive malignant cases. Of note, a KRAS G60R variant was detected in the 1 indeterminate case. A repeat FNA also yielded a diagnosis of atypia of undetermined significance. Because KRAS codon 60 alterations have not been implicated in tumorigenesis, this variant was considered to be predictive of a benign process. Similarly, detection of KDR K286N and APC I1557Y variants in 1 benign case were also classified as not likely being tumorigenic in a thyroid nodule. Unexpectedly, a NRAS Q61R mutation was detected in 1 benign case. On clinical follow-up, the patient had no issues related to the thyroid nodule. No gene translocations were detected in the 23 specimens (0%). Follow-up molecular testing was performed on available surgical resection specimens. Of cases with a preceding indeterminate cytology diagnosis, BRAF V600E was detected in the case with insufficient nucleic acid on cytology. In the case with an indeterminate cytology diagnosis of suspicious for follicular neoplasm and a resection diagnosis of papillary thyroid carcinoma, follicular variant, no molecular variants were detected (Figure 2). Follow-up molecular testing on the surgical resection specimens with a malignant cytology diagnosis but no molecular alterations detected on cytology found PTEN N323fs*21 in 1 case and no molecular variants in the other. Of the cases with a malignant cytology diagnosis and BRAF V600E detected, 1 case had follow-up molecular testing on the resection specimen that confirmed the BRAF V600E mutation. DISCUSSION We demonstrate that thyroid FNA needle rinses, which would otherwise be discarded, are an adequate source for molecular diagnostics testing using next-generation sequencing to detect gene mutations and gene transloca- Arch Pathol Lab Med Vol 142, February 2018 Molecular Testing on Residual Thyroid FNAs Fuller et al 181
5 Figure 3. A and B, Thyroid fine-needle aspiration: papillary thyroid carcinoma, no gene mutations detected. C and D, Resection: follicular neoplasm with neuroendocrine features, PTEN N323fr*21 mutation (Diff-Quik stain, original magnification 3200 [A]; Papanicolaou stain, original magnification 3200 [B]; hematoxylin-eosin, original magnifications 3100 [C] and 3400 [D]). tions. 8,10,11 Our next-generation sequencing data are consistent with those of Krane et al, 8 who used polymerase chain reaction to detect BRAF and RAS point mutations and RET/PTC and PAX8/PPARc rearrangements in 597 FNA rinse specimens. 8 They also generated interpretable results in most cases, including 90 with an indeterminate cytology diagnosis. Similarly, others have successfully analyzed DNA from residual thyroid FNA material collected in an ethanolbased fixative solution 10 or used rinses in CytoLyt with the ThyGenX reference laboratory. 11 We detected molecular variants in approximately 20% (5 of 23) of our cohort, including 1 of 9 benign, 0 of 8 indeterminate, and 4 of 6 malignant cytology diagnoses. The mutations detected were of a similar pattern as has been previously reported, 8,11,12 including NRAS in a case with benign cytology, and BRAF V600E in 4 cases with malignant cytology that were confirmed to be papillary thyroid carcinoma on surgical resection. We also report 1 indeterminate case with a likely benign KRAS variant and another with KDR and APC variants detected. To our knowledge, only 1 other KDR variant has been reported in the thyroid, in a pediatric patient with an encapsulated follicular variant of PTC detected after neuroblastoma treatment, so its biologic significance is uncertain. 13 One unusual case with a surgical diagnosis of follicular neoplasm with neuroendocrine features was found to have a PTEN frameshift variant (N323fs*21), which was not detected on the preceding thyroid FNA (Figure 3). Although often associated with Cowden syndrome, somatic PTEN variants have also been described in differentiated thyroid tumors. 14,15 The currently commercially available molecular tests for thyroid FNAs are thyroid-specific panels. Previously, other groups have used a general DNA hotspot panel on thyroid FNAs with variable success. 16,17 Our study supports the utility of a hot spot molecular panel rather than a thyroidspecific panel; the former has the advantage of being a test that was already validated in our clinical laboratory, has multiple applications, and is routinely performed. Additionally, the hot spot panel includes genes, such as AKT1, APC, PTEN, RB1, and TP53, that are known to be mutated in thyroid cancer 18 but may not be included in all currently commercially available thyroid panels. The newly renamed noninvasive follicular thyroid neoplasm with papillary-like nuclear features and subsequent reclassification as a nonmalignant neoplasm may cause 182 Arch Pathol Lab Med Vol 142, February 2018 Molecular Testing on Residual Thyroid FNAs Fuller et al
6 some changes in thyroid cytopathology. For example, if noninvasive follicular thyroid neoplasm with papillary-like nuclear features is considered a benign diagnosis, then the risks of malignancy in many of the Bethesda System categories may decrease. In the limited literature about noninvasive follicular thyroid neoplasm with papillary-like nuclear features thus far, these cases commonly receive an indeterminate cytology diagnosis. 19,20 Noninvasive follicular thyroid neoplasm with papillary-like nuclear features cases also have unique molecular features that may be detectable on the FNA cytology specimen. 21 Additionally, the TBSRTC is currently under revision, and the second edition may address some of these issues. 22 CONCLUSIONS Routinely discarded residual thyroid FNA needle rinses are an adequate source of DNA and RNA for molecular testing. In this modestly sized study, we demonstrate that clinically relevant gene mutations can be identified from this material. This strategy has the advantage of not needing additional FNA passes into dedicated media or a return of the patient for a repeat procedure. Although our initial results are promising, larger, well-controlled trials are needed to validate the assay for routine clinical use. This project was funded by a Houston Methodist Department of Pathology microgrant (winter 2016). References 1. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126(3): National Cancer Institute. Cancer stat facts: thyroid cancer. cancer.gov/statfacts/html/thyro.html. Accessed March 10, Ali S, Cibas E. The Bethesda System for Reporting Thyroid Cytopathology. New York, NY: Springer; Haugen BR, Alexander EK, Bible KC, et al American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1): Zhang M, Lin O. Molecular testing of thyroid nodules: a review of current available tests for fine-needle aspiration specimens. Arch Pathol Lab Med. 2016; 140(12): Benjamin H, Schnitzer-Perlman T, Shtabsky A, et al. Analytical validity of a microrna-based assay for diagnosing indeterminate thyroid FNA smears from routinely prepared cytology slides. Cancer Cytopathol. 2016;124(10): Fujii T, Asano A, Shimada K, Tatsumi Y, Obayashi C, Konishi N. Evaluation of RNA and DNA extraction from liquid-based cytology specimens. Diagn Cytopathol. 2016;44(10): Krane JF, Cibas ES, Alexander EK, Paschke R, Eszlinger M. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity. Cancer Cytopathol. 2015;123(6): Wei S, Lieberman D, Morrissette JJD, Baloch ZW, Roth DB, McGrath C. Using residual FNA rinse and body fluid specimens for next-generation sequencing: an institutional experience. Cancer Cytopathol. 2016;124(5): Kwon H, Kim WG, Eszlinger M, et al. Molecular diagnosis using residual liquid-based cytology materials for patients with nondiagnostic or indeterminate thyroid nodules. Endocinology Metab. 2016;31(4): Zhou H, Mody DR, Smith D, et al. FNA needle rinses preserved in Cytolyt are acceptable specimen type for mutation testing of thyroid nodules. J Am Soc Cytopathol. 2015;4(3): Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by thyroseq V2 next-generation sequencing assay. Cancer. 2014;120(23): Buryk MA, Picarsic JL, Creary SE, et al. Identification of unique, heterozygous germline mutation, STK11 (p.f354l), in a child with an encapsulated follicular variant of papillary thyroid carcinoma within six months of completing treatment for neuroblastoma. Pediatr Dev Pathol. 2015;18(4): Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997; 57(21): Nagy R, Ganapathi S, Comeras I, et al. Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid. 2011;21(5): Bellevicine C, Sgariglia R, Malapelle U, et al. Young investigator challenge: can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples? Cancer Cytopathol. 2016;124(11): Le Mercier M, D Haene N, De Nève N, et al. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology. 2015;66(2): Agrawal N, Akbani R, Aksoy BA, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3): Bizzarro T, Martini M, Capodimonti S, et al. Young Investigator Challenge: the morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cytology: some insights into their identification. Cancer Cytopathol. 2016;124(10): Maletta F, Massa F, Torregrossa L, et al. Cytological features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features and their correlation with tumor histology. Hum Pathol. 2016;54: Jiang XS, Harrison GP, Datto MB. Young Investigator Challenge: molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Cancer Cytopathol. 2016;124(12): Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology II. Acta Cytol. 2016;60(5): Arch Pathol Lab Med Vol 142, February 2018 Molecular Testing on Residual Thyroid FNAs Fuller et al 183
ASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate. Thyroid Nodules: How Far Have We Come?
ASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate Thyroid Nodules: How Far Have We Come? William C. Faquin, MD, PhD, Massachusetts General Hospital, Boston, MA The
More informationThe Bethesda Indeterminate Categories: An Update to Diagnosis and Molecular Testing
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital The Bethesda Indeterminate Categories:
More information3/27/2017. Disclosure of Relevant Financial Relationships. Each year over 550,000 thyroid FNAs are performed in the U.S.!!! THYROID FNA: THE GOOD NEWS
Disclosure of Relevant Financial Relationships William C. Faquin, MD, PhD Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital Professor of Pathology Harvard Medical
More informationMolecular Testing for Indeterminate Thyroid Nodules. October 20, 2018
Molecular Testing for Indeterminate Thyroid Nodules October 20, 2018 Patient 1: Left 1.0 cm AP x 1.6 cm transverse x 2.1 cm in length Well defined Isoechoic heterogeneous No calcification Grade 3 Vascularity
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationMarkers in Thyroid Nodule Evaluation. Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center
Markers in Thyroid Nodule Evaluation Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center Disclosures Quest Diagnostics (consultant) UPMC/CBLPath
More informationEBUS-TBNA Diagnosis and Staging of Lung Cancer
EBUS-TBNA Diagnosis and Staging of Lung Cancer Nirag Jhala MD, MIAC Professor of Pathology and Lab Med. Director of Anatomic Pathology and Cytopathology Lewis Katz School of Medicine@ Temple University
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationSection 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014
Policy Number 2.04.82 Molecular Markers in Fine Needle Aspirates of the Thyroid Medical Policy Section 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014 Disclaimer Our medical policies
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationHow to Handle Thyroid FNA
How to Handle Thyroid FNA Maoxin Wu, MD, PhD Chief of Cytopathology Director of Fine Needle Aspiration (FNA) and Core Biopsy Services Clinical Professor, Department of Pathology Joint appointment, Department
More informationLet s Make Sense of Present & Predict Future. In Light of Past 1/12/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Molecular Markers for Fine Needle Aspirates of Thyroid Nodules MP-065-MD-DE Medical Management Provider Notice Date: 10/15/2018;
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationAmerican Society of Cytopathology Companion Society Symposium Uses and Misuses of Ancillary Tests in Cytopathology
American Society of Cytopathology Companion Society Symposium Uses and Misuses of Ancillary Tests in Cytopathology Zubair W. Baloch. MD, PhD. Professor of Pathology, UPENN Medical Center Perelman School
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2014 Origination: 3/2013 Next Review: 3/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationTHYROID CYTOLOGY THYROID CYTOLOGY FINE-NEEDLE-ASPIRATION ANCILLARY TESTS IN THYROID FNA
ANCILLARY TESTS IN THYROID FNA Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Molecular Pathology Unit, IPATIMUP General-Secretary of the International
More informationKyle C. Strickland, MD, PhD; Brooke E. Howitt, MD; Justine A. Barletta, MD; Edmund S. Cibas, MD Jeffrey F. Krane, MD, PhD
Suggesting the Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): A Retrospective Analysis of Atypical and Suspicious Nodules Kyle C. Strickland,
More informationDilemmas in Cytopathology and Histopathology
Dilemmas in Cytopathology and Histopathology Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center, USA Objectives Discuss new WHO classification
More informationClinical Outcome for Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations Should Repeated FNA Be the Preferred Initial Approach?
Anatomic Pathology / Clinical Outcome for AUS Thyroid FNA Clinical Outcome for Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations Should Repeated FNA Be the Preferred Initial Approach?
More informationACCME/Disclosures. Questions to Myself? 4/11/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine-Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationMolecular markers in thyroid cancers
Review Article DOI: 10.18203/issn.2456-3994.IntJMolImmunoOncol20172639 Molecular markers in thyroid cancers Alpa Nimesh Patel, Siddharth Singh Department of Internal Medicine, Pramukhswami Medical College,
More informationThyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS
Thyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS Attending Pathologist Rhode Island Hospital, Providence, RI DISCLOSURE:
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Medical Policy Manual Genetic Testing, Policy No. 49 Molecular Markers in Fine Needle Aspirates of the Thyroid Next Review: April 2019 Last Review: June 2018 Effective: July 1, 2018 IMPORTANT REMINDER
More informationThe Bethesda System for Reporting Thyroid Cytopathology, Laila Khazai 11/4/17
The Bethesda System for Reporting Thyroid Cytopathology, 2017 Laila Khazai 11/4/17 In Summary No major changes for cytologists. The clinical team is faced with different risk of malignancies (ROM) associated
More informationBuilding On The Best A Review and Update on Bethesda Thyroid 2017
Building On The Best A Review and Update on Bethesda Thyroid 2017 Syed Z. Ali, MD, FRCPath, FIAC Professor of Pathology and Radiology The Johns Hopkins Hospital, Baltimore, Maryland USA TBSRTC Diagnostic
More informationFine-needle aspiration (FNA) cytology plays an important
Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules Michiya Nishino, MD, PhD; Marina Nikiforova, MD Context. Approximately 15% to 30% of thyroid nodules that undergo fine-needle
More informationThyroid Cytopathology: Weighing In The Bethesda System
Thyroid Cytopathology: Weighing In The Bethesda System V8 Conflicts No financial consideration Bias Work in the Canadian environment where litigation is less Thyroid cytology is often referred in by small
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationMedical Policy Manual. Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid. Date of Origin: April 2013
Medical Policy Manual Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid Date of Origin: April 2013 Section: Genetic Testing Last Reviewed Date: April 2014 Policy No: 49 Effective Date: July
More informationDr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester
Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy
More informationClinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease
Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease Robert L. Ferris, MD, PhD Department of Otolaryngology/Head and Neck Surgery and Yuri E. Nikiforov, MD, PhD Division of
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationNext generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationMolecular Testing and Cytopathology
Molecular Testing and Cytopathology Downsizing Precision Medicine but not Precision Georgios Deftereos, MD Assistant Professor, Pathology University of Utah School of Medicine Medical Director, Molecular
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Markers in Fine Needle Aspirates of the Thyroid Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Markers in Fine Needle Aspirates
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationThyroid FNA: Diagnosis, Challenges and Solutions. Disclosures
Thyroid FNA: Diagnosis, Challenges and Solutions Zubair W. Baloch, MD, PhD None Disclosures 1 Questions to Myself? Where We are Now? The Present 2 Reality Check There is More to How Thyroid Nodules are
More informationCN 925/15 History. Microscopic Findings
CN 925/15 History 78 year old female. FNA indeterminate lesion right thyroid lobe. Previous THY1C (UK) Bethesda category 1 cyst fluid. Ultrasound showed part solid/cystic changes, indeterminate in nature
More informationRelated Policies None
Medical Policy MP 2.04.78 BCBSA Ref. Policy: 2.04.78 Last Review: 12/27/2017 Effective Date: 03/01/2018 Section: Medicine End Date: 09/27/2018 Related Policies None DISCLAIMER Our medical policies are
More informationUsefulness of Diagnostic Qualifiers for Thyroid Fine-Needle Aspirations With Atypia of Undetermined Significance
Anatomic Pathology / AUS Qualifiers in Thyroid FNAs Usefulness of Diagnostic Qualifiers for Thyroid Fine-Needle Aspirations With Atypia of Undetermined Significance Paul A. VanderLaan, MD, PhD, 1 Ellen
More informationMedical Policy. Title: Genetic Testing- Molecular Markers in Fine Needle Aspirates (FNA) of the Thyroid
Medical Policy Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate
More informationIllumina s Cancer Research Portfolio and Dedicated Workflows
Illumina s Cancer Research Portfolio and Dedicated Workflows Michael Sohn Clinical Sales Specialist Spain&Italy 2017 2017 Illumina, Inc. All rights reserved. Illumina, 24sure, BaseSpace, BeadArray, BlueFish,
More informationDIAGNOSIS AND REPORTING OF FOLLICULAR-PATTERNED THYROID LESIONS BY FINE NEEDLE ASPIRATION
Follicular-patterned thyroid lesions, WC Faquin 1 DIAGNOSIS AND REPORTING OF FOLLICULAR-PATTERNED THYROID LESIONS BY FINE NEEDLE ASPIRATION William C. Faquin, M.D., Ph.D Department of Pathology, Massachusetts
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationHow to Use Molecular Genetic Studies in Endocrine Disease? (in the Management of Well- Differentiated Thyroid Cancer) No Conflicts to Declare
How to Use Molecular Genetic Studies in Endocrine Disease? (in the Management of Well- Differentiated Thyroid Cancer) No Conflicts to Declare Quan-Yang Duh Professor of Surgery University of California,
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationUpdate on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center
Update on Thyroid FNA The Bethesda System Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center Thyroid Nodules Frequent occurrence Palpable: 4-7% of adults Ultrasound: 10-31% Majority benign
More informationJennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA
Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology
More informationCytology for the Endocrinologist. Nicole Massoll M.D
Cytology for the Endocrinologist Nicole Massoll M.D Objectives Discuss slide preperation Definitions of adequacy ROSE (Rapid On-Site Evaluation) Thyroid Cytology Adequacy Nicole Massoll M.D. University
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationDetecting Oncogenic Mutations in Whole Blood
WHITE PAPER Detecting Oncogenic Mutations in Whole Blood Analytical validation of Cynvenio Biosystems LiquidBiopsy circulating tumor cell (CTC) capture and next-generation sequencing (NGS) September 2013
More information2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines
2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results
More informationCase #1. Ed Stelow, MD University of Virginia
Case #1 Ed Stelow, MD University of Virginia Imagine, If You Will It s 4:30 on Friday Last cytology case A thyroid FNA from outside that did not have any onsite interpretation It is from a 45-year old
More informationAPPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE
AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 9/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.78 Molecular Markers in Fine Needle Aspirates of the Thyroid Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November 26, 2014 Next
More information5/3/2017. Ahn et al N Engl J Med 2014; 371
Alan Failor, M.D. Clinical Professor of Medicine Division of Metabolism, Endocrinology and Nutrition University of Washington April 20, 2017 No disclosures to report 1. Appropriately evaluate s in adult
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Markers in Fine Needle Aspirates of the Thyroid Page 1 of 40 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Markers in Fine Needle Aspirates
More informationMolecular Diagnostics in Thyroid Tumors
USCAP 2011 Endocrine Pathology Society Companion Meeting Molecular Diagnostics in Thyroid Tumors Yuri E. Nikiforov, M.D., Ph.D. Department of Pathology University of Pittsburgh Medical Center Outline Overview
More informationSPECIMEN PREPARATION AND ADEQUACY OF THE MATERIAL
SPECIMEN PREPARATION AND ADEQUACY OF THE MATERIAL Guido FADDA, MD, MIAC Head, Cytopathology Section Department of Anatomic Pathology and Laboratory Medicine Agostino Gemelli School of Medicine and Hospital
More informationRepeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results
Anatomic Pathology / REPEAT THYROID FINE-NEEDLE ASPIRATION Repeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results Melina B. Flanagan, MD, MSPH, 1 N. Paul Ohori,
More informationNoninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)
Page of Accepted Preprint first posted on September 0 as Manuscript ERC--0 Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) Pedro Weslley Rosario, M.D.; Gabriela Franco
More informationsystem and the Bethesda system applied for reporting thyroid cytopathology
Original Research Article A comparative study between conventional system and the Bethesda system applied for reporting thyroid cytopathology M. Mamatha 1*, S. Chandra Sekhar 2, H. Sandhya Rani 3, S. Sandhya
More informationPredictors of Malignancy in Thyroid Fine-Needle Aspirates Cyst Fluid Only Cases
Predictors of Malignancy in Thyroid Fine-Needle Aspirates Cyst Fluid Only Cases Can Potential Clues of Malignancy Be Identified? Mohammad Jaragh, MD 1 ; V. Bessie Carydis, MMedSci (Cytol) 1 ; Christina
More informationSurgery; 5 Biostatisctics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
THYROID Volume 25, Number 11, 2015 DOI: 10.1089/thy.2015.0305 Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular
More informationNIFTP Cytologic Aspects
NIFTP Cytologic Aspects William C. Faquin, MD PhD Director, Head and Neck Pathology Massachusetts General Hospital & Massachusetts Eye and Ear Infirmary Boston, MA USA So, what is the story about FVPTC
More informationThyroid Nodules. Family Medicine Refresher Course Geeta Lal MD, FACS April 2, No financial disclosures
Thyroid Nodules Family Medicine Refresher Course Geeta Lal MD, FACS April 2, 2014 No financial disclosures Objectives Review epidemiology Work up of Thyroid nodules Indications for FNAB Evolving role of
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationSelect analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie
Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:
More informationINTRODUCTION. Original Article. Jiyeon Hyeon, MD 1 ; Soomin Ahn, MD 1 ; Jung Hee Shin, MD, PhD 2 ; and Young Lyun Oh, MD, PhD 1
The Prediction of Malignant Risk in the Category Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance of the Bethesda System for Reporting Thyroid Cytopathology Using Subcategorization
More informationRNA Extraction from Formalin Fixed Paraffin Embedded (FFPE) Tissue Enabling Next Generation Detection of Gene Fusions
RNA Extraction from Formalin Fixed Paraffin Embedded (FFPE) Tissue Enabling Next Generation Detection of Gene Fusions William M. Rehrauer, PhD Associate Professor University of Wisconsin School of Medicine
More informationNCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology
The Bethesda System For Reporting Thyroid Cytopathology Towards a Uniform Terminology With Management Guidelines NCI Thyroid FNA State of the Science Conference Bethesda, MD October 22-23, 2007 154 registrants
More informationClinical, Pathologic and Molecular Updates
Colorectal Cancer: Clinical, Pathologic and Molecular Updates Joanna A. Gibson, M.D./Ph.D. Yale University School of Medicine/Yale New Haven Hospital, Department of Pathology Gastrointestinal, Pancreaticobiliary
More informationPathologists role Ancillary Studies in Cytology Challenges. Pre-analytical issues. LUNG CYTOLOGY Predictive markers and molecular tests
Pathologists role LUNG CYTOLOGY Predictive markers and molecular tests Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Pathology Unit, IPATIMUP
More informationUPDATE ON THE Bethesda system for reporting thyroid cytology
UPDATE ON THE Bethesda system for reporting thyroid cytology Esther Rossi MD PhD MIAC Division of Anatomic Pathology and Cytology Catholic University of Sacred Heart Rome, Italy Present < Current State
More informationNoninvasive follicular thyroid neoplasm with papillary-like nuclear features: a single-institutional experience in Japan
2017, 64 (12), 1149-1155 Original Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a single-institutional experience in Japan Mitsuyoshi Hirokawa 1), Miyoko Higuchi 2), Ayana
More informationThyroid Tumor Management in the Era of Precision Oncology. Bryan Haugen, MD Former Fellow
Thyroid Tumor Management in the Era of Precision Oncology Bryan Haugen, MD Former Fellow Outline/Timeline Disclosures Led Afirma GEC study Writing group Thyroseqv3 study Rosetta Genomics research support
More informationTargeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders
Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Richard D. Press, MD, PhD Dept of Pathology Knight Cancer Institute Knight Diagnostic Labs Oregon Health & Science University
More informationThyroid nodules are common lesions encountered in the
Molecular Testing of Thyroid Nodules A Review of Current Available Tests for Fine-Needle Aspiration Specimens Ming Zhang, MD, PhD; Oscar Lin, MD, PhD Context. Fine-needle aspiration of thyroid nodules
More informationA Molecular Update for Cytopathology
A Molecular Update for Cytopathology Olga S. Chajewski, M.D. Assistant Professor Medical University of South Carolina Department of Pathology & Laboratory Medicine McKee Cytology Seminar April 21 st, 2018
More informationMolecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules
Original Article Endocrinol Metab 2016;31:586-591 https://doi.org/10.3803/enm.2016.31.4.586 pissn 2093-596X eissn 2093-5978 Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients
More informationUltrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events
Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events Sandrine Rorive, M.D., PhD. Erasme Hospital - Université Libre de Bruxelles (ULB) INTRODUCTION The assessment of thyroid nodules
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationPrior Authorization. Additional Information:
Genetic Testing for Cowden Syndrome - PTEN Gene MP9488 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic
More informationMolecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy
Accepted: 27 September 2017 DOI: 10.1111/cyt.12493 ORIGINAL ARTICLE Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy M. Decaussin-Petrucci
More informationWhat is the status of the technologies of "precision medicine?
Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationThyroid Nodule Management
Thyroid Nodule Management Shane O. LeBeau, MD Clinical Associate Professor of Medicine Clinical Lead, Endocrine Thyroid Unit Division of Endocrinology, Diabetes and Metabolism University of Pittsburgh
More information04/09/2018. Follicular Thyroid Tumors Updates in Classification & Practical Tips. Dissecting Indeterminants. In pursuit of the low grade malignancy
Follicular Thyroid Tumors Updates in Classification & Practical Tips Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University
More informationpreoperative BRAF p.v600e mutation analysis as an adjunctive diagnostic and prognostic tool to routine FNA.
Detection of BRAF c.1799t >A (p.v600e) Mutation Using Residual Routine Fine-Needle Aspiration Specimens of Papillary Thyroid Carcinoma Huan Zhao, 1 Zhi-hui Zhang, 1 Bin Zhou, 1 Ting Xiao, 2 Qin-jing Pan,
More informationCase #1 FNA of nodule in left lobe of thyroid in 67 y.o. woman
Challenging Cases Manon Auger M.D., F.R.C.P. (C) Professor, Department of Pathology McGill University Director, Cytopathology Laboratory McGill University it Health Center Case #1 FNA of nodule in left
More informationHEAD AND NECK ENDOCRINE SURGERY
HEAD AND NECK ENDOCRINE SURGERY OCTOBER 22-23, 2010 THE MARK HOPKINS SAN FRANCISCO, CA THYROID FNA AND CYTOPATHOLOGY THEODORE R. MILLER, MD THE THYROID NODULE Prevalence of palpable nodule: Female ~ 6%
More informationSecuenciación masiva: papel en la toma de decisiones
Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.
More information